Chlamydial infection is an infectious disease caused by members of the bacterial family Chlamydiaceae. In ordinary clinical usage, “chlamydia” usually means sexually transmitted infection with Chlamydia trachomatis. The broader term also includes trachoma, an eye disease caused by particular strains of the same species; respiratory infection caused by Chlamydia pneumoniae; and psittacosis, an animal-associated infection caused by Chlamydia psittaci. These conditions share a distinctive intracellular bacterial life cycle but differ substantially in transmission, affected tissues, and methods of control.
Genital C. trachomatis infection is especially important because it is frequently asymptomatic, readily transmitted, and capable of causing reproductive complications before it is recognized. Ocular infection remains a cause of preventable blindness in some settings, while respiratory and zoonotic infections range from mild illness to severe pneumonia. Understanding chlamydial disease therefore requires distinguishing the organisms and their clinical syndromes rather than treating all positive chlamydia tests as evidence of the same infection.
Organisms, classification, and discovery
Chlamydiae are bacteria that reproduce within host cells. The principal established human pathogens are C. trachomatis, C. pneumoniae, and C. psittaci. Other species primarily infect animals and occasionally cause human disease. Their intracellular dependence and small infectious particles once led investigators to classify them with viruses, but their cellular organization, bacterial ribosomes, genetic machinery, and susceptibility to antibacterial drugs establish their bacterial identity. They have a Gram-negative-type envelope, although routine Gram staining is not a useful diagnostic method.
C. trachomatis is traditionally divided into serovars according to antigenic differences in its major outer membrane protein. Serovars A, B, Ba, and C are principally associated with endemic trachoma. Serovars D through K cause most uncomplicated genital infections and can also infect the rectum, conjunctiva, and neonatal respiratory tract. Serovars L1, L2, and L3 cause lymphogranuloma venereum, an invasive infection involving lymphatic tissue. These groupings describe strong clinical associations rather than absolute barriers between anatomical sites.
The history of identification began with ocular disease. In 1907, Stanislaus von Prowazek and Ludwig Halberstädter described characteristic intracellular inclusions in conjunctival material from people with trachoma. In 1957, Tang Feifan and colleagues isolated the trachoma agent using embryonated chicken eggs, a major advance in demonstrating its biological nature. Subsequent culture methods connected related organisms with genital infection, neonatal conjunctivitis, and other syndromes. The development of molecular methods later made it possible to identify infections that conventional microscopy or culture frequently missed.
C. pneumoniae emerged as a distinct respiratory pathogen through investigation of isolates formerly grouped with other chlamydiae. The designation TWAR, used in earlier literature, combined the names of two important isolates. Its recognition as a separate species in 1989 clarified that common human respiratory infection was distinct from bird-associated psittacosis. A 1999 taxonomic proposal placed several species in a separate genus, Chlamydophila, producing names such as Chlamydophila pneumoniae. Current clinical and microbiological usage commonly places these organisms together in Chlamydia, although the alternative names remain visible in older publications and laboratory records.
Species and strain distinctions matter clinically. A genital C. trachomatis result does not establish psittacosis, and antibodies against one chlamydial species may not identify the cause of a current illness. Interpretation depends on the organism tested, the specimen collected, the anatomical site, and the clinical syndrome.
Distribution and routes of transmission
Genital C. trachomatis infection is among the most common bacterial sexually transmitted infections worldwide. The World Health Organization estimated approximately 128.5 million new infections among people aged 15–49 years in 2020. This is an estimate of newly acquired episodes, not a count of everyone living with infection at a particular moment. Repeat infections can contribute more than one episode, and many infections never appear in routine notification systems because they cause no recognized symptoms.
Transmission occurs through sexual contact involving infected genital or rectal secretions. Vaginal, anal, and oral exposure can establish infection at different mucosal sites, although oropharyngeal infection is less commonly detected than genital or rectal infection. Ejaculation is not necessary for transmission. Organisms may also reach the conjunctiva through direct inoculation of infected secretions. Genital infection is not ordinarily spread by casual social contact, shared meals, or toilet seats. A pregnant person with cervical infection can transmit the organism to an infant around delivery.
Reported infection rates are often highest among adolescents and young adults. The distribution reflects sexual networks, exposure patterns, biological susceptibility, and access to testing rather than a single individual characteristic. Social determinants of health, including barriers to confidential services and unequal access to timely treatment, affect both the probability of infection being detected and the likelihood that complications will develop. High reported rates can partly reflect extensive testing, whereas low reported rates may conceal substantial undiagnosed infection.
Endemic trachoma follows a different transmission pattern. Ocular and nasal secretions from an infected person can reach another person’s eyes through hands, shared materials, or eye-seeking flies. Repeated infection is concentrated in settings where water access, sanitation, and living conditions facilitate transmission. Young children are an important reservoir of active ocular infection, while the scarring consequences accumulate over years. The burden is therefore shaped by household and environmental conditions as well as by bacterial exposure.
C. pneumoniae spreads mainly through respiratory secretions between people. C. psittaci, by contrast, is usually acquired by inhaling contaminated material from infected birds, including aerosolized dried droppings or respiratory secretions. Pet birds, poultry, and occupational bird exposure can all be relevant; an infected bird need not look ill. Human-to-human psittacosis transmission has been documented but is uncommon. These differing routes explain why genital contact investigation, trachoma control, and investigation of bird-associated pneumonia require distinct public-health approaches.
Intracellular development and mechanisms of injury
Chlamydiae alternate between two principal developmental forms. The elementary body is the relatively compact, infectious form adapted to movement between cells. After attachment to a susceptible host cell, it enters a membrane-bound compartment called an inclusion. Within that compartment it differentiates into a reticulate body, a larger form specialized for growth and division. Reticulate bodies subsequently reorganize into elementary bodies, which leave the cell through lysis or extrusion and can initiate further infection.
For C. trachomatis, a laboratory developmental cycle commonly takes roughly 48–72 hours, although timing varies with strain, host cell, and environmental conditions. The inclusion is not simply a passive container: bacterial proteins modify its membrane, redirect host resources, and interfere with normal intracellular trafficking. Chlamydiae depend heavily on host metabolites and energy resources but retain their own metabolic capabilities. The older description of them as entirely metabolically inert outside host cells is therefore an oversimplification.
The organisms preferentially infect particular epithelial surfaces. Genital strains commonly infect columnar epithelial cells of the endocervix and urethra, while ocular strains infect conjunctival epithelium. Host cells detect infection and release signaling molecules that recruit inflammatory cells. This inflammation helps restrict the pathogen but also contributes to discharge, mucosal friability, tissue injury, and subsequent repair. Cell-mediated responses, including those involving T cells, are important for control, yet natural infection does not reliably produce durable protection against reinfection.
The major late complications arise from the interaction between infection, inflammation, and healing. In the fallopian tubes, inflammatory injury can damage ciliated epithelium and produce adhesions or scarring. In the conjunctiva, repeated episodes can gradually distort the eyelid and bring eyelashes into contact with the cornea. Thus, bacterial eradication and restoration of normal anatomy are different outcomes: successful antimicrobial treatment does not necessarily reverse established fibrosis or mechanical damage.
Under laboratory stresses such as nutrient restriction or exposure to certain immune mediators, chlamydiae can develop enlarged, aberrant forms with altered replication. This phenomenon is often called persistence. Its experimental demonstration does not mean that every recurrent positive clinical test reflects a dormant, untreatable organism. Reinfection, incomplete treatment, sampling differences, and detection of residual bacterial nucleic acid are more established explanations in many clinical circumstances. The relationship between experimental persistence and specific chronic human syndromes remains an area of research, requiring separation of plausible biological mechanisms from demonstrated clinical causation.
Genital, rectal, and lymphatic disease
Uncomplicated genital infection often produces no symptoms. When symptoms occur, they generally appear after an incubation period of approximately one to three weeks, although the timing is variable and cannot reliably identify the exposure responsible. An asymptomatic infection may remain undetected for months. Absence of discomfort therefore does not establish absence of infection, and symptom resolution alone does not prove microbiological clearance.
In people with a cervix, infection can cause cervicitis, with mucopurulent endocervical discharge or bleeding induced by gentle contact with the cervix. Possible symptoms include abnormal vaginal discharge, bleeding between periods, bleeding after intercourse, and discomfort during urination. These findings are not specific to chlamydia. Vaginal symptoms may arise from other infections or noninfectious conditions, and chlamydia may coexist with another cause rather than explain every symptom.
In people with a penis, infection commonly presents as urethritis, with dysuria, urethral irritation, and clear, mucoid, or mucopurulent discharge. Chlamydia is a major cause of nongonococcal urethritis, but that syndrome also has other infectious and noninfectious causes. Epididymitis can produce unilateral scrotal pain, tenderness, and swelling, sometimes with accompanying urethral infection. Acute scrotal symptoms have a broader differential diagnosis, including conditions unrelated to infection; identifying chlamydia does not eliminate those possibilities.
Rectal infection may be asymptomatic or cause proctitis, characterized by anorectal discomfort, discharge, bleeding, and tenesmus, the sensation of needing to pass stool despite an empty rectum. Rectal infection can occur in different populations and is not confined to people who report receptive anal intercourse. Oropharyngeal infection is usually asymptomatic, and its contribution to overall transmission is less well characterized. Infection at one site does not establish that another site is infected, so clinical interpretation must remain specimen-specific.
Lymphogranuloma venereum differs from ordinary mucosal infection because L-serovar organisms invade beyond the epithelium. A small, transient genital lesion may be followed by painful regional lymph node enlargement, sometimes with suppuration. Rectal infection can instead present as marked inflammatory proctocolitis, with pain, bleeding, discharge, and systemic symptoms. This presentation can resemble inflammatory bowel disease. Untreated invasive disease can lead to strictures, fistulas, or lymphatic obstruction. Outbreaks of rectal lymphogranuloma venereum have been recognized in sexual networks in several countries, including among men who have sex with men; the clinical syndrome, rather than group membership alone, determines its diagnostic significance.
Reproductive complications, pregnancy, and neonatal infection
The most important reproductive complication is ascending infection leading to pelvic inflammatory disease. This syndrome includes inflammation of the endometrium, fallopian tubes, and adjacent pelvic structures. C. trachomatis is an important cause, but pelvic inflammatory disease is often polymicrobial. Infection can be mild or clinically unrecognized, and the severity of initial symptoms does not reliably predict the extent of later tubal damage.
Damage to the fallopian tubes can contribute to tubal-factor infertility and ectopic pregnancy, in which implantation occurs outside the uterine cavity, most commonly in a fallopian tube. Pelvic adhesions may also contribute to persistent pelvic pain. Not every untreated chlamydial infection progresses to these outcomes. Published estimates vary because studies differ in how they identify infection, measure prior episodes, ascertain treatment, and define complications. Repeated infections are particularly important because they create additional opportunities for ascending inflammation and tissue injury.
A recognized associated syndrome is perihepatitis, often called Fitz-Hugh–Curtis syndrome. Inflammation involving the liver capsule can cause right upper abdominal pain in association with pelvic infection; the liver tissue itself is not necessarily infected. Chlamydia can also trigger reactive arthritis, an inflammatory joint syndrome occurring after an infection outside the joint. Arthritis may accompany urethral and ocular symptoms, but the full historical triad is not required. This is distinct from direct bacterial invasion of a joint.
During pregnancy, cervical infection provides a source for neonatal exposure during birth. Chlamydial infection has also been associated in observational research with outcomes such as premature rupture of membranes and preterm delivery, although the strength and interpretation of individual associations vary. The clearest established neonatal syndromes are conjunctivitis and pneumonia. Their occurrence depends on maternal infection and transmission; they are not congenital malformations caused by a developmental abnormality.
Neonatal chlamydial conjunctivitis typically begins about 5–12 days after birth, with eyelid swelling and discharge that may become mucopurulent. Chlamydial pneumonia most often presents at one to three months of age. A characteristic presentation is a repetitive staccato cough, rapid breathing, and little or no fever; eosinophilia and diffuse lung abnormalities may be present. These patterns are suggestive rather than individually diagnostic. Routine ocular prophylaxis aimed at preventing gonococcal eye disease does not reliably prevent chlamydial conjunctivitis or pneumonia, which is why maternal detection and treatment have a central preventive role.
Trachoma and other ocular infections
Trachoma is a chronic keratoconjunctival disease associated with repeated ocular infection by particular C. trachomatis strains. Its clinical course differs from a single episode of conjunctivitis acquired from genital secretions. In endemic settings, repeated infections during childhood generate recurrent inflammation of the upper tarsal conjunctiva. Follicles and inflammatory thickening characterize active disease, while the later blinding stages reflect accumulated scarring rather than necessarily ongoing bacterial replication.
Conjunctival scarring can pull the eyelid inward, producing entropion. The eyelashes then rub against the eye, a condition called trichiasis. Repeated mechanical abrasion, secondary infection, and surface damage can produce corneal opacity and irreversible visual impairment. The interval between childhood infection and adult visual loss may span decades. Adult women have often borne a disproportionate burden of late disease in endemic communities, reflecting repeated exposure and caregiving patterns as well as local social conditions.
The World Health Organization’s simplified grading system distinguishes five signs: trachomatous inflammation–follicular, trachomatous inflammation–intense, trachomatous scarring, trachomatous trichiasis, and corneal opacity. These signs are useful for population assessment and programmatic decisions. They should not be interpreted as five stages that every affected person necessarily passes through in a fixed sequence. Clinical inflammation, laboratory evidence of infection, and established scarring can show different distributions within the same community.
Trachoma control uses the SAFE strategy: surgery for trichiasis, antibiotics to reduce infection, facial cleanliness, and environmental improvement. Each component addresses a different part of the disease process. Eyelid surgery changes the damaging mechanical contact between lashes and cornea; antibiotics reduce the bacterial reservoir; and environmental measures address conditions that promote repeated transmission. Elimination of trachoma as a public-health problem is defined by specified disease and service thresholds, not by proof that every ocular chlamydial infection has disappeared.
Adult inclusion conjunctivitis is usually associated with genital serovars rather than the classic trachoma strains. It can produce a persistent follicular conjunctivitis, often initially affecting one eye, with discharge and preauricular lymph node enlargement. Concurrent genital infection may be asymptomatic. Because the infection can involve sites beyond the eye, topical eye treatment alone does not address its full distribution. Neonatal inclusion conjunctivitis represents another distinct setting, arising from perinatal exposure rather than the repeated community transmission underlying endemic trachoma.
Respiratory infections and animal-associated disease
C. pneumoniae causes respiratory infections ranging from pharyngitis and bronchitis to community-acquired pneumonia. Many infections are mild or asymptomatic, and reinfection occurs. Clinical illness can develop gradually, with sore throat, hoarseness, headache, and a persistent cough. Pneumonia may be less abrupt than some other bacterial pneumonias, but clinical features overlap extensively with viral infection and other causes of atypical pneumonia. Neither a characteristic cough nor a particular radiographic pattern identifies the organism reliably.
Respiratory outbreaks have occurred in settings with sustained close contact, including schools, military facilities, and residential institutions. The organism’s incubation period is generally longer than that of many common respiratory viruses, often measured in weeks. This can make chains of transmission difficult to reconstruct from symptoms alone. Older adults and people with underlying illness may experience more serious disease, although the presence of C. pneumoniae in a test result still requires interpretation in the clinical context.
Psittacosis is caused by C. psittaci. Its historical name reflects its association with parrots and related birds, but numerous avian species can carry the organism. Exposure may occur during bird handling, cage cleaning, poultry processing, veterinary work, or contact with contaminated environments. Outbreaks can therefore involve pet owners, workers, or people with indirect exposure rather than a remembered bird bite or obvious contact with a sick animal. The usual route is inhalation, not inoculation through the skin.
The incubation period for psittacosis is commonly about 5–14 days, although longer intervals occur. Illness can include high fever, severe headache, muscle aches, dry cough, and pneumonia. Gastrointestinal symptoms, abnormal liver tests, or neurological manifestations may accompany respiratory disease. Severe infection can involve multiple organs. A bird-exposure history is diagnostically valuable, but its absence does not exclude the disease, since environmental exposure may be unrecognized. Psittacosis cannot be distinguished confidently from all other pneumonias by symptoms alone.
Other animal-associated chlamydial infections are uncommon but clinically relevant. Chlamydia abortus, chiefly a pathogen of sheep and goats, can cause severe illness and pregnancy loss after human exposure to infected animal tissues, particularly birthing products. Such infections belong to zoonotic disease rather than ordinary sexually transmitted chlamydia. Historical claims that C. pneumoniae is a major treatable cause of atherosclerotic disease have not been established by clinical intervention evidence. Detection of microbial material in tissue, an antibody association, and proof that treating an organism improves a disease are different levels of evidence.
Laboratory diagnosis and interpretation
For genital and extragenital C. trachomatis, nucleic acid amplification tests are the principal diagnostic method. These assays detect specific bacterial genetic sequences and generally provide better sensitivity than older antigen tests or routine culture. Appropriate specimens include vaginal swabs, first-catch urine, and site-specific rectal or oropharyngeal swabs, depending on the assay and clinical setting. Self-collected vaginal swabs perform well when obtained using validated procedures and can reduce some barriers associated with examination-based sampling.
The sampling site is fundamental. A negative urine test does not exclude an isolated rectal infection, and a positive rectal result does not establish infection of the cervix or urethra. For urogenital testing in women, vaginal swabs are generally more sensitive than urine. In men, first-catch urine is a commonly used specimen. First-catch sampling means the initial portion of the urinary stream, not the midstream specimen usually collected for a conventional bacterial urinary tract infection culture.
A nucleic acid test detects its molecular target, not necessarily a living organism. After effective treatment, residual nucleic acid may remain detectable for several weeks. Testing too soon can therefore produce a positive result that does not represent viable persistent infection. Conversely, sampling very soon after exposure can miss an infection that has not yet reached detectable levels. Test interpretation also depends on diagnostic sensitivity and specificity and on the frequency of infection in the population being tested.
Culture requires susceptible living cells and specialized laboratory methods because chlamydiae do not grow on ordinary bacteriological media. It remains useful in selected circumstances but is technically demanding and less convenient than molecular testing. Serological testing has limited value for diagnosing uncomplicated current genital infection: antibodies may reflect previous exposure, may cross-react, and do not identify the anatomical site. In suspected lymphogranuloma venereum, a positive C. trachomatis molecular result from the affected site can be supplemented by strain-specific molecular testing, although such testing is not universally available.
Respiratory and zoonotic infections require different diagnostic pathways. Molecular testing of suitable respiratory specimens can identify C. pneumoniae or C. psittaci where available. For psittacosis, paired antibody samples may support a diagnosis when they show a significant rise, but results are often retrospective and cross-reactions complicate interpretation. Culture of C. psittaci poses an important laboratory exposure hazard. In suspected pelvic inflammatory disease, a negative lower-genital-tract chlamydia test does not by itself exclude upper-tract inflammation or infection, so laboratory findings and clinical findings answer related but different questions.
Antimicrobial treatment and follow-up
Chlamydial infections are treatable with antibiotics that reach intracellular organisms. Tetracyclines and macrolides are central drug classes, while some fluoroquinolones have activity in selected settings. Drug choice and duration differ among uncomplicated genital infection, lymphogranuloma venereum, pelvic inflammatory disease, pregnancy-associated infection, neonatal disease, and psittacosis. A single standard regimen cannot be applied to every infection merely because all involve a species of Chlamydia.
Major guidelines describe a seven-day doxycycline course as a preferred treatment for uncomplicated C. trachomatis infection in nonpregnant adolescents and adults. Single-dose azithromycin remains an alternative in specified circumstances, but comparative evidence has shown lower microbiological efficacy for rectal infection. This difference matters because rectal infection may be present without recognized symptoms. Apparent failure after treatment can reflect reinfection, incomplete dosing, residual nucleic acid, or an unrecognized anatomical reservoir; it does not automatically demonstrate antibiotic resistance.
Pregnancy changes the available treatment options. Azithromycin is a recommended treatment in major guidelines, with amoxicillin used as an alternative in some guidance. Neonatal infection requires systemic treatment, usually with an appropriate macrolide, because topical treatment alone does not eradicate nasopharyngeal or other extraocular infection. Macrolide exposure in very young infants has a recognized association with infantile hypertrophic pyloric stenosis, a safety consideration incorporated into clinical monitoring and prescribing decisions.
Invasive or complicated syndromes require different treatment structures. Lymphogranuloma venereum generally receives a longer doxycycline course, commonly 21 days in guidelines. Pelvic inflammatory disease requires coverage for other likely organisms in addition to chlamydia. Doxycycline is a principal treatment for psittacosis, with alternatives considered for particular age groups or circumstances. For trachoma, antibiotic use may be organized at community level rather than restricted to individually symptomatic patients, because reducing the reservoir is a programmatic objective.
Follow-up distinguishes a test of cure from retesting for reinfection. A test of cure assesses whether the initial episode was eradicated and is particularly important during pregnancy; major guidance places this at approximately four weeks after treatment. Routine early tests of cure are not generally part of uncomplicated management in nonpregnant people when treatment has been completed and no other concern exists. Retesting around three months addresses the substantial frequency of repeat infection. Partner evaluation and treatment are central to preventing reinfection. Expedited partner therapy is an established approach in some jurisdictions, but its use depends on local law, the clinical situation, and the infections being considered.
Prevention, surveillance, and research priorities
Prevention of genital chlamydia combines reduction of exposure, detection of asymptomatic infection, timely treatment, and management of sexual partners. Barrier methods reduce transmission when used consistently and correctly, although protection is not absolute. Because symptoms miss many infections, screening has a different purpose from testing a person with urethritis or cervicitis. Population recommendations vary by country, age, anatomy, sexual exposure, pregnancy status, and local epidemiology; they are not interchangeable with universal testing of every person at every visit.
In the United States, major recommendations support annual screening of sexually active women younger than 25 years and older women with specified risk factors. Recommendations for men are more dependent on population and setting, with site-specific testing important in groups with substantial extragenital infection. Prenatal screening policies aim both to identify maternal infection and to prevent neonatal disease. The evidence supporting screening is strongest for detecting infection and reducing some reproductive complications; estimating its effect on population-wide transmission is more complex.
Public-health surveillance usually measures diagnosed and reported cases rather than all infections. Trends are influenced by test availability, screening intensity, assay sensitivity, access to care, and reporting practices. A rise in notifications can reflect increased transmission, improved detection, or both. Conversely, a decrease during service disruption may reflect fewer tests rather than fewer infections. Surveys estimating prevalence and models estimating incidence address different questions from routine case reporting and depend on different assumptions.
No licensed human vaccine currently prevents chlamydial infection. Vaccine development must contend with strain diversity, incomplete natural immunity, and the need to protect mucosal surfaces without intensifying harmful inflammation. In 2019, a first-in-human phase 1 trial of the CTH522 vaccine candidate reported safety and immune-response findings. Such early-phase findings do not establish protection against infection, infertility, or transmission. Later development must evaluate clinically meaningful outcomes as well as laboratory immune responses.
Other research priorities include rapid molecular testing close to the point of care, better prediction of which infections progress to reproductive damage, and methods that improve partner treatment without compromising confidentiality. Studies of doxycycline post-exposure prophylaxis have shown reductions in some bacterial sexually transmitted infections in selected populations, but those findings cannot be generalized to every group; antimicrobial resistance and effects on other bacteria remain important questions. In trachoma programs, continuing research addresses transmission after mass treatment, antibiotic use, and the environmental conditions that sustain recurrence. Across these fields, detecting fewer organisms, preventing tissue damage, and interrupting transmission remain distinct outcomes that require separate measurement.